



Neoadjuvant Therapy for Breast Cancer

Guest Editor:

Dr. Luigi Cavanna

Oncologia Medica ed
Ematologia, USL di Piacenza,
Ospedale Guglielmo da Saliceto,
29121 Piacenza, Italy

Deadline for manuscript
submissions:

closed (10 January 2023)

Message from the Guest Editor

Neoadjuvant chemotherapy (associated or not with target therapy) has become an important therapeutic choice in the treatment of locally advanced and early-stage breast cancer. The goal of neoadjuvant treatment is not only to reduce the tumor volume, allowing radical surgery, but also to be able to achieve less invasive surgery both on the breast (lumpectomy vs. mastectomy), and axilla (sentinel node biopsy vs. axillary dissection) in case of downstaging. Moreover, neoadjuvant chemotherapy has an important predictive and prognostic role.

We are pleased to invite you to write an article for this Special Issue on neoadjuvant chemotherapy for locally advanced and early-stage breast cancer. This Special Issue aims to improve knowledge regarding neoadjuvant therapy for breast cancer.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: breast cancer, neoadjuvant, adjuvant, pathological complete response, biomarkers, chemotherapy, and target therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)